By Fineline Cube 
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has entered into a licensing agreement with Taiwan-based HanchorBio. This collaboration grants Fosun exclusive rights to develop, manufacture, and commercialize HanchorBio’s SIRPα-Fc fusion protein HCB101 in China (excluding Taiwan), selected Southeast Asian countries, and specific MENA region nations, with priority negotiation rights for Japan.
Licensing Agreement
Under the terms of the agreement, HanchorBio will receive an upfront payment of USD 10 million and is eligible for USD 192 million in milestone payments, along with sales royalties.
Drug Profile
HCB101 is a potential best-in-class Fc fused SIRP alpha variant. It is formed by fusing the engineered IgV domain of human signal regulatory protein alpha (SIRP alpha) with the IgG4Fc domain. Compared to traditional anti-CD47 monoclonal antibodies, HCB101 offers significant advantages in optimizing immune activation and reducing hematological toxicity.
Clinical Development
HCB101 is currently undergoing Phase Ib/IIa clinical studies in combination with standard therapy for advanced solid tumors in China, the US, and other regions. Preliminary results indicate efficacy and good safety, both as a standalone treatment and in combination with other drugs.-Fineline Info & Tech